Francisco J. Esteva: The surprising truth about breast cancer in young women who are BRCA mutation carriers
Francisco J. Esteva shared on Linkedin:
”The surprising truth about breast cancer in young women who are BRCA mutation carriers. When we think of hormone receptor-positive breast cancer, we usually expect a better prognosis. But for young women with BRCA1/2 mutations, the story changes.
45.5% had hormone receptor-positive breast cancer.
54.5% had hormone receptor-negative disease.
Here’s what stood out:
1\. Recurrence patterns:
• More distant recurrences in hormone receptor-positive disease.
• More second primary cancers in hormone receptor-negative disease.
2\. Survival:
• 8-year disease-free survival: 65.8% for HR-positive vs. 63.4% for HR-negative.
• The gap closes after 5 years.
• Overall survival: Worse prognosis after 5 years for hormone receptor-positive patients.
3\. Tumor subtypes:
• Unlike the general population, luminal A-like tumors in BRCA carriers have the worst long-term prognosis.
4\. Prognostic value:
• Hormone receptor-positive status doesn’t hold the same protective value in BRCA carriers, particularly for those with luminal A-like disease.
Key takeaway: Women with hormone receptor-positive breast cancer in this group may benefit from escalated treatments, while BRCA1 carriers might consider risk-reducing surgery. This study sheds light on the need for tailored management for young BRCA carriers. It’s not one-size-fits-all anymore. What’s your take on this personalized approach to cancer care?
P.S. If you found this insightful, consider resharing to spread the word.”
Source: Francisco J. Esteva/Linkedin
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023